Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Science

ADC Development


Print article Print article

2014-08-20 12:44:27 - SMi is proud to announce that PhotoBiotics Ltd, will be hosting the ADC Development masterclass taking place on the 3rd December 2014 in Central London

This full-day Masterclass will comprise technical guidance on how to make drugs ready for bioconjugation, antibody-drug conjugation strategies with some basic analytical tools.

ADC Development will survey the state-of-the-art in ADC technology giving an insight into which new approaches may lead to novel drug candidates with unique features and benefits. The bulk of the masterclass will comprise technical guidance on how to make drugs ready for bioconjugation, antibody-drug conjugation strategies with some basic analytical tools. There will be plenty of time for interactive discussion and dissemination of best practice.

PhotoBiotics Ltd is a multidisciplinary company spun out from Imperial College London. The PhotoBiotics R&D team has already succeeded in its initial objective of targeting photosensitiser-based drugs to tumours, generating compelling efficacy data

in various orthotopic and xenograft models, and has a product ready to enter preclinical toxicology/clinical development.

Masterclass leaders include:
- Mahendra Deonarain, Chief Science Officer
- Gokhan Yahioglu, Co-founder and Director of Chemistry
- Ioanna Stamati, Team Leader

For a conference programme visit: www.smi-online.co.uk/conjugates4.asp
For more information contact: Alex McCann on +44 (0) 207 827 6128 or email amccann@smi-online.co.uk

---END---

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at www.smi-online.co.uk

About PhotoBiotics Ltd:
PhotoBiotics Ltd is a multidisciplinary company spun out from Imperial College London to explore ways of targeting drugs directly to tumours, thus enhancing the efficacy of cancer treatment while also reducing deleterious side-effects. The Company has developed a unique and simple antibody-drug conjugate (ADC) technology platform, denoted OptiLink, which enables the multiple attachment of drugs to antibody fragments. Counter-intuitively, OptiLink allows higher drug loadings on antibody fragments than normally achieved with whole monoclonal antibodies. The PhotoBiotics' R&D team has already succeeded in its initial objective of targeting photosensitiser-based drugs to tumours, generating compelling efficacy data in various orthotopic and xenograft models, and has a product ready to enter preclinical toxicology/clinical development. The Company has raised new funds is now starting a 2-year program exemplifying how Optilink has utility across a wide range of other ADC applications.


Contact Information:
SMi Group Ltd

2nd Floor South, Harling House
47-51 Great Suffolk Street
London
SE1 0BS
United Kingdom

Contact Person:
Teri Arri
Marketing Executive
Phone: +44 (0) 20 7827 6162
email: email

Web: www.smi-online.co.uk/conjugates4.asp



Author:
Daniel Lee
e-mail
Web: www.smi-online.co.uk/
Phone: 02078276078

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com